Novo Nordisk: EPS up 29% in Q1
The Danish pharmaceutical company, which specializes in the treatment of diabetes and obesity, saw sales rise by 22% (+24% at CER) to over 65.3 billion, supported in particular by the US market.
For 2024 as a whole, at TCC, sales growth is now expected to be between 19% and 27%, and operating profit between 22% and 30%, target ranges up one point on previous ones.
Copyright (c) 2024 CercleFinance.com. All rights reserved.
Go to the original article.
Contact us to request a correction